Dr. Brian Haynes received his Ph.D. degree from the Department of Computer Science at Washington University in St. Louis. His doctoral work focused on the integration of RNA-Seq and ChIP-Seq technologies to model transcriptional networks that regulate carcinogenesis and microbial pathogenesis. Brian joined Asuragen in November of 2012 as a Senior Scientist in the Computational Biology group. Since joining Asuragen, he has spearheaded the initiative to adopt whole transcriptome (WT) RNA-Seq as a tool for broad unbiased biomarker discovery. He has applied WT RNA-Seq to discover novel diagnostic markers in thyroid cancer and identify patient response stratification signatures in late phase drug trials. Brian has also led the research and development effort of translating these discoveries into a clinical assay format with targeted RNA-Seq.